PMDA drug package insert
リフヌア錠45mg
PMDA Prescription drug · MSD株式会社 · package insert Jun 24, 2025
Key facts
| Brand names | リフヌア錠45mg |
|---|---|
| Nonproprietary names | ゲーファピキサントクエン酸塩 |
| Companies | 製造販売元／MSD株式会社, 発売元／杏林製薬株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 選択的P2X3受容体拮抗薬; ◎咳嗽治療薬◎ |
| Therapeutic category codes | 87229 |
| YJ codes | 2290001F1028 |
| Approval numbers | 30400AMX00008000 |
| Package insert edition | 第5版 |
| Package insert date | Jun 24, 2025 |
| PMDA document key | 170050_2290001F1028_1 |
| PMDA company code | 170050 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: